Gibb A, Jones C, Bloor A, Kulkarni S, Illidge T, Linton K, Radford J. Brentuximab vedotin in refractory CD30+ lymphomas: a bridge to allogeneic transplantation in approximately one quarter of patients treated on a Named Patient Programme at a single UK center. Haematologica [Internet]. 2013Mar.31 [cited 2026Nov.14];98(4):611-4. Available from: https://haematologica.org/article/view/6631